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INTRODUCTION
Newborn screening (NBS) for inherited metabolic diseases 
(IMDs) is a representative public healthcare project conduct-
ed worldwide. In Korea, about 80% of newborn babies under-
go NBS for approximately 40 to 50 IMDs. However, only 6 
IMDs (congenital hypothyroidism, congenital adrenal hyper-
plasia, phenylketonuria, maple syrup urine disease, galacto-
semia, and homocystinuria) have been performed free of 
charge by the government and other IMDs are not financially 
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Purpose: We developed a new workflow design which included results from both biochemical and targeted gene sequencing 
analysis interpreted comprehensively. We then conducted a pilot study to evaluate the benefit of this new approach in newborn 
screening (NBS) and demonstrated the efficiency of this workflow in detecting causative genetic variants.
Materials and Methods: Ten patients in Group 1 were diagnosed clinically using biochemical assays only, and 10 newborns in 
Group 2 were diagnosed with suspected inherited metabolic disease (IMD) in NBS. We applied NewbornDiscovery (SD Genomics), 
an integrated workflow design that encompasses analyte-phenotype-gene, single nucleotide variant/small insertion and dele-
tion/copy number variation analyses along with clinical interpretation of genetic variants related to each participant’s condition.
Results: A molecular genetic diagnosis was established in 95% (19/20) of individuals. In Group 1, 13 and 7 of 20 alleles were clas-
sified as pathogenic and likely pathogenic, respectively. In Group 2, 11 and 6 of 17 alleles with identified causative variants were 
pathogenic and likely pathogenic, respectively. There were no variants of uncertain significance. For each individual, the New-
bornDiscovery and biochemical analysis results reached 100% concordance, since the single newborn testing negative for caus-
ative genetic variant in Group 2 showed a benign clinical course.
Conclusion: This integrated diagnostic workflow resulted in a high yield. This approach not only enabled early confirmation of 
specific IMD, but also detected conditions not included in the current NBS. 
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covered by the government.1 Traditionally, abnormal NBS re-
sult warrants differential diagnosis of the suspected disease, 
based on an analysis of specific enzymatic or biochemical 
features in the blood or urine specimens (Fig. 1A). The Ameri-
can College of Medical Genetics and Genomics (ACMG) has 
developed and established action sheets and algorithms that 
provide next steps for differentiation of conditions associated 
with the same or similar metabolic profiles (https://www.
ncbi.nlm.nih.gov/books/NBK55827/). However, it is not easy 
to differentiate IMDs based on biochemical analysis of me-
tabolites alone, which is occasionally impracticable in a clini-
cal setting.2 Furthermore, even different diseases that affect the 
same metabolic component have distinct and specific treat-
ments and prognoses. In this scenario, a molecular genetic 
analysis and identification of causative genetic variants are of-
ten required to confirm specific disease. Sanger sequencing 
may require several weeks to distinguish multiple diseases or 
genes. Therefore, empirical treatment is usually provided while 
awaiting the final results.3
Recently, several multi-gene panels based on next genera-
tion sequencing (NGS) have been developed and validated to 
facilitate simultaneous and cost-effective analysis of multiple 
genes related to IMDs or severe primary immunodeficiency. 
In particular, satisfactory NGS results were obtained with only 
a small amount of DNA, utilizing minimally invasive procedures 
with dried blood spots (DBS) or saliva within 1−3 weeks.4-6
Here, we introduce a new analytical workflow which includes 
results from both NBS/biochemical assays and targeted gene 
panel analysis interpreted simultaneously. We demonstrated 
the efficiency of this workflow for the detection of causative 
genetic variants in clinically diagnosed patients. 
MATERIALS AND METHODS
Study participants and study design
The Institutional Review Boards of Seoul National University 
Hospital approved and monitored this study (H-1601-079-734). 
All study participants (parent, legal guardian, and/or child) 
provided written informed consent to participate in the study. 
Twenty participants were enrolled into 2 groups (Tables 1 and 
2) with each group comprising 10 subjects. No participant had 
a family history of consanguineous marriage. Group 1 included 
patients who had been clinically diagnosed with specific IMD 
based on clinical and biochemical criteria, and were managed 
prior to enrollment in this study (Table 1). Six of the 10 patients 
had a type of lysosomal storage disease (LSD) that was not 
screened by the current NBS in Korea. We analyzed the detec-
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Follow-up tests
 • Biochemical analysis
 • Enzyme activity
 • Blood, urine, tissue, etc.
Conclusive
 •  Clinical diagnosis:  
IMDI, IMD2, IMD3... 
Diagnosis confirmation
Comparison of analysis results
Comprehensive diagnosis
 • Counseling
 • Treatment/management
Continue
treament/management
Inconclusive
 •  Discrepancy between 
results of follow-up  
tests
Gene analysis
 • Gene 1, Gene 2, Gene 3...
False positive NBS 
findings or benign 
condition
Stop treatment
NewbornDiscovery analysis
 • Targeted NGS panel: 259 genes
 •  Analysis of analytes- 
phenotypes-genes
 •  Concurrently analyses of SNVs, 
INDELs, and CNV
 •  Clinical interpretation of  
genetic variants
Definite No identification of causative genetic 
variants
Indefinite
Fig. 1. Algorithms for diagnosis of IMDs in newborns. Conventional (A) and newly integrated (B) algorithms are presented for the diagnosis of IMDs in 
newborns suspected with a specific disease on NBS. In contrast to the conventional approach, the newly integrated approach is based on standard 
biochemical and targeted gene panel analyses concurrently, and data from each analysis are compared and reaffirmed to enable rapid disease di-
agnosis. IMD, inherited metabolic disease; NBS, newborn screening; DBS, dried blood spot; NGS, next generation sequencing; SNV, single nucleo-
tide variant; INDEL, small insertions and deletions; CNV, copy number variations.
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tion rate of causative genetic variants and the concordance rate 
between clinical and molecular diagnosis in this group. Group 
2 included newborns referred with abnormal NBS tests in an 
actual clinical setting (Table 2). We performed a pilot prospec-
tive clinical study in which this new analytical workflow (New-
bornDiscovery, SD Genomics, Seoul, Korea) was applied si-
multaneously during follow-up standard biochemical tests of 
plasma and urine metabolites (Fig. 1B).
New analytical workflow for NBS
NewbornDiscovery is an integrated workflow design that en-
compasses concurrent analyte-phenotype-genes (step 1) with 
single nucleotide variant (SNV)/small insertion and deletion 
(INDEL)/copy number variation (CNV) analyses (step 2), as 
well as the clinical interpretation of genetic variants according 
to the 2015 ACMG standards/guidelines (step 3) (Fig. 2A).7 An 
NGS panel for NewbornDiscovery comprised 259 genes relat-
ed to 196 IMDs (including endocrinopathies), 9 hemoglobin-
opathies, 4 congenital non-hemolytic hyperbilirubinemias, 23 
immunodeficiencies, and 17 hearing losses (Supplementary 
Table 1, only online). After the step 1 (abnormal analyte-phe-
notype-gene analysis), based on the associated phenotypes, 
clinical urgency, and incidental findings, NewbornDiscovery 
categorized the genes as A (candidate genes directly associat-
ed with phenotype), B [genes associated with critical condi-
tions according to the 2014 Society for Inherited Metabolic 
Disorders position statement (http://www.simd.org/Issues/) 
regardless of candidate genes], or C (neither candidate genes 
nor genes associated with critical conditions) (Fig. 2A). A clas-
sification of identified and reported genetic variants was used 
differentially according to the gene category (Fig. 2B). In the 
present study, a preliminary report of genes in categories A 
and B was generated within 5 days. After additional testing to 
confirm the NGS results, a secondary report for genes in cate-
gories A and B was generated within 2 weeks, and final report-
ing was completed within 3 weeks.
Analysis and interpretation of variants, and validation 
of NGS data
A customized panel using a hybridization capture approach 
was designed to enrich DNA fragments spanning the genes of 
interest. This panel covered whole coding exons (CDS) and 
Abnormal NBS findings Category A
Inheritance patterns
No. of genetic variants identified according to the 
classification
Pathogenic or 
likely pathogenic
Uncertain 
significance
Likely benign 
or benign
Autosomal dominant ≥1 ≥1 Not reported
Autosomal recessive ≥1 ≥1 Not reported
X-linked dominant ≥1 ≥1 Not reported
X-linked recessive ≥1 ≥1 Not reported
Category B and Category C
Inheritance patterns
No. of genetic variants identified according to the 
classification (zygosity)
Pathogenic or 
likely pathogenic
Uncertain 
significance
Likely benign 
or benign
Autosomal dominant ≥1 Not reported Not reported
Autosomal recessive 
≥1 (homozygote) 
≥2 (heterozygote)
Not reported Not reported
X-linked dominant ≥1 Not reported Not reported
X-linked recessive 
≥1 (male) 
≥1 (female: homozygote) 
≥2 (female: heterozygote)
Not reported Not reported
Step 1. Analysis: Abnormal analyte(s)-phenotype(s)-gene(s)
Preliminary reporting for genes in the category A and B within 5 days
Step 2. Analysis: Concurrent analysis of SNV/INDEL/CNV 
Initial interpretation according to the 2015 ACMG standards/guidelines
Step 3. Analysis: 
Clinical interpretation according to the 2015 ACMG standards/guidelines
Secondary reporting for genes in the category A and B within 2 weeks 
Final reporting for genes in the category A, B, and C within 3 weeks
Confirmation testing of NGS results: 
Targeted Sanger sequencing, qPCR, testing of parents (if possible), etc.
Category A. Candidate 
genes
Category B. Genes 
associated with critical 
conditions regardless of 
candidate genes
Category C. Genes which 
are neither candidate 
genes nor genes as-
sociated with critical 
conditions
Fig. 2. An integrated workflow design for NBS. The NewbornDiscovery workflow features a 3-step analysis (A) for identification of the reported range 
of genetic variants (B) in the present study. The reported time and range are determined according to the gene category after step 1 analysis. Cate-
gory B includes genes associated with critical conditions, according to the 2014 Society for Inherited Metabolic Disorders position statement (http://
www.simd.org/Issues/), regardless of candidate genes. NBS, newborn screening; SNV, single nucleotide variant; INDEL, small insertions and dele-
tions; CNV, copy number variations; ACMG, American College of Medical Genetics and Genomics; NGS, next generation sequencing; qPCR, quantita-
tive PCR.
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known pathogenic variants in UTR, introns, or promoters in 
corresponding genes. In order to adequately cover the CDS 
regions and detect CNV with high accuracy, the probes of all 
target regions were tiled at a density higher than 3× on average. 
Genomic DNA was extracted from DBS (total 2 circles mea-
suring 1 cm in diameter; total 4 paper punches with 3.0−3.5 
mm in diameter in detail). DNA was isolated on a Chemagic 
360-D instrument (PerkinElmer, Baesweiler, Germany), based 
on magnetic bead technology, using a Chemagic STAR DNA 
Blood200 kit (PerkinElmer, Waltham, MA, USA) according to 
the manufacturer’s instructions. DNA concentrations were 
determined using Qubit 3.0 Fluorometer (Invitrogen, Carls-
bad, CA, USA). The total genomic DNA yield of each sample 
was approximately 100−200 ng. 
Isolated genomic DNA was fragmented, bar-coded with li-
brary adapters, and incubated with oligonucleotide probes. Se-
quencing was performed with 2×150 bp NextSeq runs (Illumi-
na, San Diego, CA, USA). The NGS quality control matrix was at 
least 200× mean reads on target with a minimum of 20× cov-
erage on >99.9% target bases. We used an integrated clinical 
interpretation platform, based on the NewbornDISCOVERY 
workflow for variant analysis, according to the 2015 ACMG stan-
dards/guidelines.7
The sequence reads were aligned to the human reference 
genome (GRCh37/hg19) with decoy sequences (hs37d5) us-
ing BWA-MEM (version 0.7.12) with the default option.8 The 
SNVs and INDELs were called using the Genome Analysis Tool-
kit HaplotypeCaller (version 3.4.46).9 Variant calling was per-
formed with a minimum of 10 reads. Minimum mapping and 
base quality scores of 20 and 10, respectively, were required to 
call a variant. The variants were annotated using ANNOVAR.10
CNVs were called using DeviCNV (version 1.0, SD Genomics, 
manuscript in preparation) developed for exon level CNV de-
tection from targeted gene panel sequencing data, based on 
read depth analysis. DeviCNV provides a score summarizing 
quality (confidence intervals of copy number ratios, number of 
probes supporting the candidates, regression qualities, etc.) 
for each CNV candidate, and plots for target genes containing 
copy number ratio with confidence interval of each target probe 
to help users select clinically relevant CNV candidates for fur-
ther validation. 
To obtain the frequencies of variants in large populations, we 
used five population databases: the Exome Aggregation Con-
sortium (ExAC; http://exac.broadinstitute.org/), the Exome 
Variant Server (EVS; http://evs.gs.washington.edu/EVS/), the 
1000-Genome Project (1000 GP; http://www.internationalge-
nome.org/), the Korean Reference Genome Database (KRG-
DB; http://152.99.75.168/KRGDB/menuPages/intro.jsp), and 
the dbSNP (https://www.ncbi.nlm.nih.gov/SNP/). Locus-
specific databases, such as the ClinVar (https://www.ncbi.nlm.
nih.gov/clinvar/), the Human Genome Mutation Database 
(HGMD; http://www.hgmd.org/), and the Leiden Open Vari-
ation Database (LOVD; http://www.lovd.nl/3.0/home), were 
used to assess the supporting evidence of benign impact or 
pathogenicity (BP6 or PP5 according to the 2015 ACMG stan-
dards/guidelines). To determine possible structural or func-
tional damage due to a missense mutation, we used multiple 
lines of in silico software such as SIFT,11 PolyPhen-2,12 Muta-
tionTaster,13 and FATHMM.14 We also used dbscSNV to predict 
whether a variant affects alternative splicing.15 
We reviewed previously published literature for functional 
analysis of variants (BS3, PM1, or PS3), population frequen-
cies (BS1 or PS4), or segregation (BS4 or PP1), using an inte-
grated interpretation platform based on expert manual reviews. 
Finally, we classified variants into pathogenic, likely pathogen-
ic, of uncertain significance, likely benign, or benign categories.
All suspicious SNVs or INDELs associated with patients’ dis-
orders were validated with Sanger sequencing. In the case of 
abrupt decrease in the sequencing depth of specific exons us-
ing DeviCNV, we performed exon-based quantitative PCR to 
detect and validate large deletions containing one or several 
exons. Quantitative real-time PCR (qPCR) was performed us-
ing a QuantStudio 3 real-time PCR system (Applied Biosys-
tems, Foster City, CA, USA). Specific primers were designed for 
targeted exons and GAPDH (as a control housekeeping gene). 
All qPCR reactions were performed in a 20 μL final volume with 
500 nM each of PCR primers, 2 μL template DNA, and POW-
ER UP SYBR master mix (Applied Biosystems). The qPCR was 
carried out with an initial denaturation step at 95°C for 10 min, 
followed by 40 cycles of denaturation at 95°C for 15 s and an-
nealing/extension at 60°C for 1 min. The segments of the tar-
geted exons and GAPDH were amplified in triplicate for each 
DNA sample derived from both patient and control subjects. 
The relative quantity of targeted exons was determined using 
the 2-ΔΔCt method,16 and the results were normalized against 
GAPDH as an endogenous control.
 
RESULTS
NGS analysis 
The average reads on target of NewbornDISCOVERY gene 
panel were 414×. In addition, the NewbornDISCOVERY gene 
panel yielded 99.9% coverage at 20× coverage and 95.4% cov-
erage at 100× coverage. NGS analysis results are shown in Sup-
plementary Table 2 (only online).
Clinical and biochemical characteristics of Group 1: 
the clinical diagnosis group
Ten patients in Group 1 were previously diagnosed via bio-
chemical analysis (Table 1). Six of them presented with typical 
symptoms and signs in accordance with underlying LSDs, 
three (CD_6−8) with Pompe’s disease (OMIM#232300), two 
(CD_3, 4) with Morquio A disease (OMIM#253000), and one 
(CD_9) with Gaucher’s disease (OMIM#230800). They were 
clinically diagnosed, based on an analysis of specific enzyme 
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activity and/or pathologic findings of affected tissues at the 
mean age of 52±49 months (range 8 months−11 years). All pa-
tients were undergoing treatment with enzyme replacement 
therapy at the time of enrollment. The other four patients 
showed abnormal NBS results without manifesting symptoms 
or signs, and were clinically diagnosed, based on biochemical 
studies of plasma and urine metabolites at the mean age of 
29±11 days (range 20−42 days). Two patients diagnosed with or-
ganic acidemia, CD_1 with methylmalonic acidemia (OMIM# 
251000) and CD_5 with isovaleric acidemia (IVA, OMIM# 
243500), were managed with a low protein diet with special 
milk. CD_2 with methionine adenosyltransferase I/III defi-
ciency (MATD, OMIM#250850) was followed without methio-
nine restriction. CD_10 with short chain acyl-CoA dehydroge-
nase deficiency (SCADD, OMIM#201470) was managed with 
riboflavin supplementation together without prolonged fast-
ing. All the 10 patients were followed for 58±28 months and 
showed normal neuropsychological development.
 
Molecular genetic analysis of group 1 patients based 
on NewbornDiscovery
We identified causative genetic variants in all 20 alleles derived 
from the Group 1 patients (20/20), and the detection rate of 
NewbornDiscovery in this group was 100% (Table 1). The clini-
cal significance of all identified causative genetic variants was 
classified as pathogenic (13/20) or likely pathogenic (7/20) 
according to the 2015 ACMG standards/guidelines.7 No allele 
in this group was classified as a variant of uncertain significance 
in the genes under category A.
Eight patients were compound heterozygotes, and all the 
identified variants were confirmed trans by parental testing. The 
other two patients were homozygous for either c.466-3_466-
2delinsGG on IVD (CD_5) or p.(Pro55Leu) on ACADS (CD_10). 
Clinical and biochemical characteristics of group 2 
undiagnosed in the pilot study group 
All 10 subjects enrolled in this group were newborns with ab-
normal NBS results (Table 2). The mean age at enrollment was 
10.4±5.5 days (range 3−21 days), the mean gestational age was 
38.9±1.3 weeks, and no premature infants were enrolled. Their 
mean birth weight was 3.2±0.4 kg, and all newborns except 
one (UD_8 with a birth weight of 2.52 kg) showed an appro-
priate weight for their gestational age. We assessed these pa-
tients biochemically using conventional clinical and molecu-
lar diagnostic approaches simultaneously according to the 
protocol indicated in Fig. 1B.
Based on the results of biochemical assays, five patients 
were diagnosed with possible organic acidemias: UD_8 with 
propionic academia (OMIM#606054), UD_3 and 5 with IVA, 
and UD_1 and 4 with multiple acyl-CoA dehydrogenase defi-
ciency (MADD, OMIM#231680). Three patients tested positive 
for a diagnosis of aminoacidopathies: UD_7 with argininosuc-
cinic aciduria (ASLD, OMIM#207900), UD_6 with MATD, and 
UD_10 with hyperprolinemia (OMIM#239500, #239510). Two 
patients were suspected to have fatty acid oxidation disorders: 
UD_2 with SCADD and UD_9 with systemic carnitine deficien-
cy (SCD, OMIM#212140) or carnitine palmitoyltransferase 1A 
deficiency (CPT1D, OMIM#255120). In case of UD_9, the 
findings in the results obtained from initial NBS varied from 
the follow-up quantitative plasma carnitine profiles. Although 
this female patient was referred with an abnormally low free 
carnitine level on NBS, her quantitative plasma carnitine pro-
files showed a low acylcarnitine level, but normal total and 
free carnitine levels. These results were inconsistent with the 
diagnosis of SCD, but suggested the possibility of CPT1D. 
Although 7 of 10 newborns showed no subjective symptoms 
or signs related to specific IMD, 3 newborns presented with 
clinical symptoms and signs of metabolic crisis even before 
NBS results were obtained (60 h after birth for UD_3, 18 h for 
UD_4, and 58 h for UD_8). These 3 patients required neonatal 
intensive care for 5−17 days, and UD_4 with MADD died at 20 
days due to unresolved metabolic acidosis, hyperammonemia, 
respiratory difficulty, and loss of normal reflexes. We initiated 
and continued with general and disease-specific manage-
ment according to presumptive IMDs, based on biochemical 
findings, in order to prevent the onset or worsening of compli-
cations, until confirmation or exclusion of specific IMDs. Ex-
cept for UD_4 who died in the neonatal period, the other new-
borns manifested normal developmental milestones without 
any acute metabolic crisis, although the average duration of fol-
low-up was only 9 to 12 months in this group.
 
Molecular genetic analysis by NewbornDiscovery of 
group 2 patients
We found causative genetic variants in 17 of 20 alleles in 9 of 10 
Group 2 patients, and the disease confirmation rate of New-
bornDiscovery in this group was 90% (Table 2). UD_6 was di-
agnosed with an autosomal dominant form of MATD carrying 
a single heterozygous variant. The other eight subjects (UD_1−5, 
UD_7−9) were diagnosed with autosomal recessive inherited 
disorders with two independently segregating mutant alleles 
(1 from each parent). Parental testing revealed 4 variants in-
volving UD_1 (c.831+3A>C in ETFDH), UD_4 [p.(Arg452Gly) 
in ETFDH], UD_7 [p.(Pro156Leu) in ASL], and UD_9 [p.(Leu-
97Val) in SLC22A5], which were confirmed trans with a patho-
genic variant on the other allele. Accordingly, the ACMG cate-
gories were adjusted for uncertain significance to likely 
pathogenic status. Therefore, the clinical significance of all 
identified causative genetic variants was classified as patho-
genic (11/17) or likely pathogenic (6/17).7 Three patients (UD_1, 
UD_4, and UD_7) showed a deletion allele across one to sev-
en exons of the causing gene, which was confirmed by quan-
titative PCR. The clinical significance of these CNVs was clas-
sified as pathogenic.7
Two IVA patients (UD_3 and 5) in group 2 carried the same 
homozygous pathogenic variant in IVD, c.466-3_466-2delin-
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sGG, as CD_5 from group 1. Furthermore, the UD_6 harbored a 
variant, p.(Arg249Gln), which was also identified in CD_2.
There was only one patient (UD_10) who was not molecu-
larly diagnosed via NewbornDiscovery analysis in the present 
study. Hyperprolinemia type 1 or 2 was suspected based on 
elevated proline levels (2.1−2.4 fold higher than the cut-off 
value) in repeated NBSs. However, no meaningful variant in 
PRODH or ALDH4A1 was detected using NewbornDiscovery, 
and no suspicious evidence of large deletions affecting both 
alleles was found from NewbornDiscovery data. Interestingly, 
the plasma proline levels measured in our hospital showed a 
tendency to decrease without any abnormality in other meta-
bolic and chemistry studies. The high proline levels on NBS 
might have been transient and not pathologically correlated.
DISCUSSION
Traditionally, the medical screening protocol for newborns 
with abnormal NBS is shown in Fig. 1A. Recurrent abnormal 
results detected on NBS warrant follow-up biochemical tests 
for diagnosis and management. Follow-up biochemical tests 
usually include plasma amino acid analysis, urine organic 
acid analysis, specific enzyme assays, and measurements of 
toxic metabolites such as ammonia, ketones, and lactic acid. 
However, discrepancies between the results of biochemical 
tests have often been observed, and biochemical enzyme as-
says are labor-intensive and tedious, and yield semiquantita-
tive results.2,17 In such cases, Sanger sequencing is the next 
step employed to confirm and differentiate the diagnosis. How-
ever, Sanger sequencing is also expensive and is hampered by 
the genetic heterogeneity of IMDs, which may result in de-
layed confirmation of diagnosis. In addition, although tan-
dem mass spectrometry (TMS)-based NBS facilitates simulta-
neous detection of approximately 40−50 metabolites, new 
therapeutic agents have been developed for the treatment of 
various IMDs, many of which are not currently included in the 
NBS lists.18
Multi-gene panels based on NGS techniques represent a po-
tential alternative and complement the current NBS. They are 
associated with minimal ethical implications related to whole 
exome/genome sequencing by avoiding secondary findings 
or findings that cannot be interpreted. NBS should be targeted 
to diseases that are clinically well defined and medically ac-
tionable. Due to possible secondary findings associated with 
genome-based tests that are independent of the original pur-
pose of NBS, a targeted gene analysis involving multi-gene 
panel is recommended to integrate NGS-based tests with the 
NBS.19 The NewbornDISCOVERY analysis is focused on both 
diagnostic and proactive applications, and provides uncertain 
to positive results of suspected disorders (in the gene category 
A) for the diagnostic use. Incidental findings, which are vari-
ants in the genes under categories B and C, are reported with 
clear results for proactive use: 1 or more pathogenic or likely 
pathogenic variants for autosomal dominant disorders, 1 ho-
mozygous pathogenic/likely pathogenic variant or 2 hetero-
zygous pathogenic/likely pathogenic variants for autosomal 
recessive disorders.
The application of NGS techniques to NBS is technically 
feasible. Recent studies show that DNA can be successfully 
extracted from DBS for conventional NBS,4,6 and one of the 
studies reported an analytical sensitivity of 99.8%.4 However, 
the NGS analysis and interpretation are still insufficient and 
difficult. Above all, the difficulty in interpreting variants of un-
certain significance (VUS) should be considered, because the 
database of genotype-phenotype correlation is insufficient at 
present. Furthermore, these VUS are detected frequently 
(Supplementary Table 2, only online). In addition, it is well 
known that clinical phenotype varies even among family mem-
bers affected with the same genotype.
The general price of clinical NGS testing (e.g., approximately 
500−3000 USD for clinical NGS panel testing) depends on the 
number of genes analyzed, the range of interpretation or con-
sultation, or inclusion of secondary validation testing. It ex-
ceeds 2000 USD for clinical whole exome sequencing and is 
higher than NBS (approximately 100−200 USD), biochemical 
assays (approximately 100−500 USD), or targeted Sanger se-
quencing (approximately 500−1500 USD for whole coding ex-
ons) alone. However, if a patient is finally diagnosed with a spe-
cific IMD, the new integrated approach (NBS combined with 
NGS testing) reduces the total diagnostic cost compared with 
the conventional approach. It is possible to confirm the spe-
cific disease earlier, if NGS is implemented at an appropriate 
stage of the diagnostic process. In addition, it covers most IMDs 
at low cost, compensates for false-positive results of current 
NBS, and leads to the identification of new causative genetic 
variants.4,5,20
In this study, we used a newly introduced analysis workflow, 
NewbornDiscovery, which comprises 259 genes including 
those associated with newly treatable or actionable diseases 
(Supplementary Table 1, only online). In sequence data ob-
tained through multi-gene panel sequencing, many heterozy-
gous variants that are not associated with the patient’s actual 
disease are concurrently identified. Biochemical data are in-
dispensable for the interpretation of the clinical significance 
of these identified variants and also for the exclusion of or fo-
cus on specific diseases. By executing these two different ele-
ments of the workflow in parallel and comparing the results of 
analysis with each other, we not only achieved a higher rate of 
disease confirmation in a shorter time frame, but also initiat-
ed management of a specific IMD earlier and provided accu-
rate genetic counseling to each patient.
In the present study, both patients diagnosed with MADD 
(UD_1 and 4) harbored different novel sequence variants in 
an ETFDH allele. The c.831+3A>C from UD_1 was predicted 
to affect RNA splicing by in silico analyses,15 although analysis 
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of cDNA constructed from the patient’s RNA was necessary 
for confirmation. The p.(Arg452Gly) from UD_4 is a missense 
variant. In a previous report, a MADD type C patient harbored 
a variant at the same amino acid, p.(Arg452Lys). However, the 
clinical significance of this variant has yet to be identified.21 
Therefore, based on sequence data alone, these two variants 
were initially interpreted as VUS.7 However, abnormal bio-
chemical findings to suggest MADD may be considered con-
currently using the NewbornDiscovery approach. The NGS 
data were meticulously investigated focusing on ETFDH, and 
a large deletion (exons 1−7 for UD_1 and exons 7−8 for UD_4) 
was quickly found on the other allele using DeviCNV. Finally, 
the variants c.831+3A>C and p.(Arg452Gly) were re-classified 
as likely pathogenic after confirmation of their location in trans 
to the deletion allele by parental testing.7 The p.(Pro156Leu) 
on ASL from UD_7 was a novel variant, and on another vari-
ant in the same amino acid, p.(Pro156Arg) has been reported, 
in an ASLD patient.22 By identifying a deletion in the other al-
lele using the NewbornDiscovery, we established the molecu-
lar diagnosis of ASLD. In total, 3/37 mutant alleles in this study 
(8.1%) were identified as deletion CNVs.
In the present study, we found additional benefits of New-
bornDiscovery, shown in the UD_9 case. The results of the pa-
tient’s TMS and plasma carnitine profiles were not consistent, 
and the two suspected conditions, SCD and CPT1D, required 
different medical management. L-carnitine supplementation 
is the mainstay of management for SCD,23 whereas CPT1D re-
quires a low-fat and high-carbohydrate diet instead of L-car-
nitine supplementation.24 Based on NewbornDiscovery, we 
found two causative genetic variations in SLC22A5 and con-
firmed the diagnosis of SCD within 2 weeks (and a prelimi-
nary report within 5 days), thus facilitating prompt disease-
specific treatment for UD_9. The likely pathogenic variant, 
p.(Leu97Val) located in the first extracellular loop, existed in 
trans to the pathogenic variant, p.(Trp132*). The Asp91 site 
near Leu97 is a protein glycosylation site, and normal glycosyl-
ation plays an important role in carnitine recognition. Further-
more, a known pathogenic variant near Asp91, p.(Arg83Leu), 
impairs glycosylation and transfer of the mature protein to the 
plasma membrane.25
Persistent hypermethioninemia is a unique IMD, character-
ized by both autosomal dominant and autosomal recessive 
inheritance depending on the type of causative variants. In the 
autosomal dominant type, p.(Arg264His) is the most frequently 
identified variant worldwide,25 whereas p.(Arg249Gln) is com-
monly found in Korean patients.26 
A majority of patients, especially those carrying the autoso-
mal dominant type, show no clinical abnormalities. Mean plas-
ma methionine concentrations show a positive correlation 
with brain abnormalities on imaging and regular monitoring 
of plasma methionine levels is recommended.25 In the present 
study, CD_2 and UD_6 were diagnosed with autosomal reces-
sive and autosomal dominant forms of persistent hyperme-
thioninemia, respectively. The p.(Arg249Gln) was identified 
in both patients, however, CD_2 carried another recessively in-
herited variant, p.(Arg299Cys),27 and showed higher methio-
nine levels than those of UD_6. An understanding of the genetic 
subtypes via NewbornDiscovery facilitates appropriate individ-
ual genetic counseling, and prognostic evaluation of the disease.
In the present study, we identified recurrent IMD-related 
causative variants in Koreans. The c.466-3_466-2delinsGG is 
the only individual IVD variant found in this study, and all three 
IVA patients were homozygous for this variant. The c.466-3_466-
2delinsGG on IVD was first detected in Korean IVA patients 
and has been shown to be the most common IVD causative 
variant identified in Korea.28 Considering that each patient is 
independent of the others and born out of non-consanguine-
ous marriage, it may represent a founder effect. Two variants 
associated with ACADS [p.(Pro55Leu) and p.(Glu344Gly)] 
and detected as homozygotes in CD_10 and UD_2, have also 
been recurrently identified in Korean and Japanese SCADD 
patients.29-31
In conclusion, the newly developed multi-gene panel, New-
bornDiscovery, and the new diagnostic approach combined 
with biochemical data yielded satisfactory results in both dis-
ease confirmation and exclusion. A small amount of blood ob-
tained from a minimally invasive procedure is sufficient to com-
plete the analyses, even in newborns. This approach not only 
compensates for the disadvantages of current NBS, but also 
reduces medical costs and socioeconomic losses associated 
with delayed diagnosis of IMDs. Considering the develop-
mental direction of NBS expansion, we expect that simultane-
ous testing of TMS and multi-gene panel will become the first-
tier NBS in the future.
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